Abstract:Abstract Background Immune checkpoint blockade (ICB) therapy targeting the programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis has achieved considerable success in treating a wide range of cancers. However, most patients are still resistant to ICB and lack of optimal biomarkers to predict response. Thus, uncovering the underlying cellular and molecular determinants of ICB resistance is needed to improve the efficacy of anti-PD-1/L1 therapy. Palmitoylation is mediated by a family of 23 S-acyltransferases, Asp-His‐His‐Cys type (ZDHHC) palmitoyltransferases, that precisely control various cancer-related protein functions, representing promising drug targets for cancer therapy. However, how specific ZDHHC palmitoyltransferases affect the tumour microenvironment (TME) and augment the therapeutic efficacy of ICB remains elusive. Methods Five syngeneic subcutaneous tumour models were used to demonstrate the anti-tumour activity of ZDHHC9 deficiency. Multispectral flow cytometry was used to characterize alterations in immune cell subsets. Two poorly immunogenic tumour models were used to evaluate the synergistic effect of ZDHHC9 deficiency and anti-PD-L1 therapy. A polymeric nanoparticle approach was developed for the in vivo delivery of ZDHHC9-siRNA to tumour tissues. The TGCA database was used to assess the expression pattern and immunological characteristics of ZDHHC9 in pan-cancers. Results We found that tumor cell-intrinsic “immuno-oncogene” Zinc Finger DHHC-Type Containing 9 (ZDHHC9) was overexpressed in various human cancers and associated with impaired anti-tumor immunity. In five syngeneic tumour models, the knockdown of ZDHHC9 expression in tumour cells was sufficient to suppress tumour progression and improve survival by reprogramming the immunosuppressive (‘cold’) to proinflammatory (‘hot’) TME. Furthermore, ZDHHC9 deficiency in tumour cells sensitized anti-PD-L1 immunotherapy in CD8+ T cells dependent manner. Lastly, we employed the ZDHHC9-siRNA nanoparticle system to efficiently silence ZDHHC9 in tumours whilst potentiating anti-PD-L1 immunotherapy in non-immunogenic tumours. Conclusion Tumour-intrinsic S-palmitoylation regulator ZDHHC9 tumour expression is a mechanism of inhibition of host anti-tumour immunity and reprogramming of immunosuppressive tumour microenvironment. Inactivating ZDHHC9 highlights an effective immunotherapeutic strategy and booster for anti-PD-L1 therapy.

Palmitoylation of TIM-3 promotes immune exhaustion and restrains antitumor immunity

TIM-3, a Promising Target for Cancer Immunotherapy

TIM-3 restrains anti-tumour immunity by regulating inflammasome activation

Interaction of TIM4 and TIM3 Induces T Helper 1 Cell Apoptosis

Long Non-Coding RNA Lnc-Tim3 Exacerbates CD8 T Cell Exhaustion Via Binding to Tim-3 and Inducing Nuclear Translocation of Bat3 in HCC.

TIM-3 As a Target for Cancer Immunotherapy and Mechanisms of Action.

Tim-3: An Activation Marker and Activation Limiter of Innate Immune Cells

Beyond T cell exhaustion: TIM-3 regulation of myeloid cells

T-cell immunoglobulin and mucin-domain containing-3 (TIM-3): Solving a key puzzle in autoimmune diseases

PUB044 TIM-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes

Targeting ZDHHC9 enhances anti-PD-L1 immunotherapy efficacy by reprogramming the tumour microenvironment

T Cell Ig and Mucin Domain–Containing Protein 3 Is Recruited to the Immune Synapse, Disrupts Stable Synapse Formation, and Associates with Receptor Phosphatases

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

Co-expression of TIM-3 and CEACAM1 promotes T cell exhaustion in colorectal cancer patients

Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8+ T cell exhaustion and anti-PD-1 resistance

Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-κB/IL-6/STAT3 axis

TIM3 is a context-dependent co-regulator of cytotoxic T cell function

DNA demethylation of the TIM-3 promoter is critical for its stable expression on T cells

Tim-3 Expression Defines Regulatory T Cells in Human Tumors

Tim-3 promotes tumor-promoting M2 macrophage polarization by binding to STAT1 and suppressing the STAT1-miR-155 signaling axis.

Circulating and Tumor-Infiltrating Tim-3 in Patients with Colorectal Cancer.